Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence – Authors' reply

TY - JOUR

T1 - Osilodrostat for the treatment of Cushing's disease

T2 - efficacy, stability, and persistence – Authors' reply

AU - “Consensus on diagnosis and management of Cushing's disease: a guideline update”

AU - Fleseriu, Maria

AU - Castinetti, Frederic

AU - Gadelha, Mônica

AU - Giustina, Andrea

AU - Lacroix, André

AU - Melmed, Shlomo

AU - Newell-Price, John

AU - Pivonello, Rosario

AU - Reincke, Martin

AU - Biller, Beverly M.K.

N1 - Funding Information: MF has received grants to the institution from Novartis, Strongbridge, Novo Nordisk, Crinetics, Millendo, Ascendis, and Pfizer; personal honoraria for consulting and advisory boards from Crinetics, HRA Pharma, Novartis, Recordati, Strongbridge, Sparrow, Ascendis, Novo Nordisk, and Pfizer; is Deputy Editor for European Journal of Endocrinology; and has served on the Board for the Pituitary Society. FC has received personal honoraria for consulting, lectures, and support for meeting attendance from Recordati Rare Diseases, Ipsen, and HRA Pharma. MG has received grants to the institution from Novartis and Ipsen; personal honoraria for consulting, lectures, and advisory boards from Crinetics, Recordati Rare Diseases, Novo Nordisk, and Ipsen; has served on the Board of the Brazilian Society of Endocrinology and Metabolism; and is President of the Pituitary Society. AG has received grants to the institution from Pfizer; personal honoraria for consulting and advisory boards from Abiogen, Novo Nordisk, and Recordati; and has served on the Board or as an advisor to the European Hormone and Metabolism Foundation and Glucocorticoid Induced Osteoporosis Skeletal Endocrinology Group. AL has received grants from Recordati and Corcept for clinical trials; personal honoraria and education grants for lectures, support for meeting attendance, and participation in advisory boards from Pfizer, Ipsen, Corcept, Recordati, and the European Journal of Endocrinology; royalties from UpToDate Endocrinology; and has served as a Board member for the International Society of Endocrinology. SM has received grants to the institution from the US Food and Drug Administration; non-financial support from Cyclacel; and has served on the Board of the Pituitary Society. JN-P has received grants and honoraria to the institution for consulting and advisory boards from Diurnal, HRA Pharma, Crinetics, Recordati, and Novartis; and has served as a Board member or advisor for the Pituitary Foundation and Endocrine Society. RP has received grants to the institution from Novartis, Pfizer, Ipsen, Shire, IBSA Farmaceutici, HRA Pharma, Cortendo, Corcept Therapeutics, and Merck Serono; personal honoraria for consulting, lectures, support for meeting attendance, and advisory boards from Novartis, Shire, HRA Pharma, Cortendo, Pfizer, Recordati, IBSA Farmaceutici, and Crinetics Pharmaceuticals; and has served on the board of the Pituitary Society. MR has received personal honoraria for consulting, lectures, and advisory boards from Novartis, Recordati, HRA Pharma, and Ipsen; and is President of the European Society of Endocrinology. BMKB has received grants to the institution from Ascendis, Novartis, Strongbridge, and Millendo; personal honoraria for consulting from Aeterna Zentaris, Ascendis, Merck Serono, Novartis, Novo Nordisk, Recordati, Strongbridge, and Sparrow; and has served as an advisor for the Endocrine Society.

PY - 2022/6

Y1 - 2022/6

UR - http://www.scopus.com/inward/record.url?scp=85130864210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130864210&partnerID=8YFLogxK

U2 - 10.1016/S2213-8587(22)00135-8

DO - 10.1016/S2213-8587(22)00135-8

M3 - Letter

C2 - 35597255

AN - SCOPUS:85130864210

SN - 2213-8587

VL - 10

SP - 385

EP - 387

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

IS - 6

ER -